Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.38 |
| ▸ | CDC25B | P30305 | 8/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | FGF1 | P05230 | 1/20 | 0.34 |
| ▸ | FGF2 | P09038 | 1/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410626 | 0.92 | PTPN1 (0.43) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL26349670 | 0.91 | NPC1 (0.40) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL26349638 | 0.81 | SSTR3 (0.41) | — | |
| SCHEMBL26354489 | 0.80 | SLC6A2 (0.38) | TNFNOTUM | |
| SCHEMBL29410617 | 0.79 | PTPN1 (0.42) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL30530241 | 0.76 | SSTR3 (0.41) | — | |
| SCHEMBL990249 | 0.74 | PTPN1 (0.48) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL22750896 | 0.74 | PTPN1 (0.48) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL19479697 | 0.73 | PTPN1 (0.48) | TNFPTPN1CDC25BPTPN2PTPN6 | |
| SCHEMBL38652098 | 0.73 | PTPN1 (0.49) | TNFPTPN1CDC25BPTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | REYOUNG CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303618-A1 | TRIPTOLIDE CONJUGATES AND USES THEREOF | TLR9, XIAP, ENPP2 | TNF 131/4885PTPN1 736/4885CDC25B 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.